About Us
Management
Board of Directors
Investors
Product Candidates
Product
Candidate
Indication(s)
Description
Development Status
Zelrix
Acute migraine
Sumatriptan single-use transdermal patch.
Expected NDA submission during fourth quarter of 2010.
Pivotal Phase III clinical trial completed.
Two ongoing Phase III safety trials.
Two ongoing pharmacokinetic trials in healthy subjects.
NP201
Parkinson’s Disease
Ropinirole two-month implant.
Expected Investigational New Drug submission during first half of 2011.
Preclinical proof of concept completed.
NP202
Schizophrenia and Bipolar Disorder
Atypical antipsychotic three-month implant.
Expected Investigational New Drug submission expected in 2012.
Prototype development in progress.
Home
|
About Us
|
Research and Development
|
Press Room
|
Contact
Legal Notices
|
Privacy Policy
Search
Copyright © 2005-2010 NuPathe Inc.